Neuralink Expands Brain Implant Trials with 12 Global Patients 
Silver Prices Hit Record Highs: How Silver Is Traded and Why Demand Is Surging 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
China LNG Imports Rise in December as Long-Term Contracts Drive Growth 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
European Defense Stocks Slide as Trump Signals Progress in Ukraine-Russia Peace Talks 
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Asian Stock Markets Trade Narrowly as Year-End Volumes Thin, KOSPI Outperforms on Tech Rally 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns 
Oil Prices Rise as Ukraine Peace Talks and Middle East Tensions Stir Supply Concerns 
U.S. Stock Futures Slip as Year-End Trading Turns Cautious 
Keio University researchers have successfully transplanted into a patient with a severe spinal cord injury two million neural progenitor cells derived from other people’s iPS cells as part of a clinical study, offering hope for the paralyzed.
The patient is doing well.
Over the next year, while the patient undergoes rehabilitation, the team of doctors will see how safe and effective the treatment is.
The treatment is designed for patients with “complete paralysis” who are within two to four weeks of sustaining a spinal cord injury, called the subacute phase.
The iPS cells used were stockpiled by Kyoto University’s Center for iPS Cell Research and Application.
While rehabilitation is currently the only effective treatment for a spinal cord injury, the team believes that the transplanted cells could repair damaged neural circuits and create new tissue that can transmit signals from the brain.
The team plans to do the transplant into four more patients with spinal cord injuries.
While Japan’s Ministry of Health, Labor, and Welfare approved this clinical trial in February 2019, the process of finding suitable patients was postponed due to the COVID-19 pandemic.
